Abstract 315P
Background
Cetuximab (an inhibitor of EGFR) is commonly utilized for the treatment of head and neck cancers. It has been employed in combination with radiation or multi-agent chemotherapy for locoregionally advanced and metastatic head and neck cancer respectively. This study explored the use of cetuximab plus an JAK1 inhibitor (JAK1i), which is a protein that is downstream in EGFR signaling, in order to test whether this dual inhibition could accentuate the effects of cetuximab.
Methods
Human head and neck squamous cell cancer cells (UM-SCC-6 cells) were cultured as previously described (Bonner JA et al., BMC Cancer 15:673). The JAK1 inhibitor (JAK1i) was obtained from Calbiochem, LaJolla, CA. Standard assays of immunoblots, proliferation, apoptosis and comet assays were utilized (Bonner JA et al., BMC Cancer 15:673).
Results
The combination of cetuximab (0.5 μg/ml) and JAK1i (1µM) resulted in greater inhibition of STAT-3 than either agent alone on immunoblot analysis. Likewise, the combination treatment resulted in greater inhibition of cell proliferation (at 72 hours), greater apoptosis and enhanced DNA double strand breaks (comet) compared to either agent given alone.
Conclusions
Cetuximab initially showed activity in head and neck cancer over 20 years ago. It is currently used in combination with radiation or chemotherapy for these patients. The results reported herein suggest that the anti-proliferative effects of cetuximab can be enhanced with the addition of JAK1 inhibition. Further work exploring the targeting of various steps in EGFR signaling is warranted in head and neck cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
James A. Bonner.
Funding
Has not received any funding.
Disclosure
J.A. Bonner: Honoraria (institution), Advisory / Consultancy: Bristol-Myers Squibb Company; Honoraria (institution), Advisory / Consultancy: Eli Lily and Company; Honoraria (institution), Advisory / Consultancy: Merck Serono; Honoraria (institution), Advisory / Consultancy: Cel-Sci. E. Yang: Advisory / Consultancy, Research grant / Funding (institution): AstraZeneca; Research grant / Funding (institution): Eli Lilly. All other authors have declared no conflicts of interest.
Resources from the same session
174P - Progression of computer aided diagnosis on gastric cancer
Presenter: Yingyan Yu
Session: Poster display session
Resources:
Abstract
175P - Hypermethylation of the PCDHB15 promoter predicts the prognosis in gastric cancer
Presenter: Yu-ting Lee
Session: Poster display session
Resources:
Abstract
176P - DCLK1 promotes tumour invasion and metastasis through epithelial-mesenchymal transition and the MEK/ERK pathway in esophageal squamous cell carcinoma
Presenter: Jiannan Yao
Session: Poster display session
Resources:
Abstract
177P - Comparison of nab-paclitaxel plus ramcirumab and paclitaxel plus ramcirumab in patients with pretreated metastatic gastric cancer
Presenter: Yosuke Horita
Session: Poster display session
Resources:
Abstract
178P - Chief cell in stomach have stem cell activity and potential to develop gastric cancer
Presenter: Akihiro Yamamura
Session: Poster display session
Resources:
Abstract
179P - Postoperative Adjuvant transarterial chemoembolization versus surgery alone for resected hepatocellular carcinoma: A propensity-score matching study
Presenter: Mingyu Chen
Session: Poster display session
Resources:
Abstract
180P - LHPP inhibit the cell proliferation and EMT via the TGFβ/SMAD3 signaling pathway in iCCA
Presenter: Dan Wang
Session: Poster display session
Resources:
Abstract
181P - The emerging role of third-line gemcitabine plus nab-paclitaxel in advanced pancreatic adenocarcinoma
Presenter: Andrew Dean
Session: Poster display session
Resources:
Abstract
182P - Durable response to second-line m-FOLFIRINOX for advanced pancreatic adenocarcinoma in patients with performance status of two or less
Presenter: Adarsh Das
Session: Poster display session
Resources:
Abstract
183P - Epidemiologic profile of gastric cancer in East Azerbaijan, Iran: 2 years population-based cancer registry results
Presenter: Pooneh Jabbaripour
Session: Poster display session
Resources:
Abstract